Fibromyalgia - New Concepts of Pathogenesis and Treatment
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Fibromyalgia (FMS) is a debilitating disorder characterized by chronic diffuse muscle pain, fatigue, sleep disturbance, depression and skin sensitivity. There are no genetic or biochemical markers and patients often present with other comorbid diseases, such as migraines, interstitial cystitis and irritable bowel syndrome. Diagnosis includes the presence of 11/18 trigger points, but many patients with early symptoms might not fit this definition. Pathogenesis is still unknown, but there has been evidence of increased corticotropin-releasing hormone (CRH) and substance P (SP) in the CSF of FMS patients, as well as increased SP, IL-6 and IL-8 in their serum. Increased numbers of activated mast cells were also noted in skin biopsies. The hypothesis is put forward that FMS is a neuro-immunoendocrine disorder where increased release of CRH and SP from neurons in specific muscle sites triggers local mast cells to release proinflammatory and neurosensitizing molecules. There is no curative treatment although low doses of tricyclic antidepressants and the serotonin-3 receptor antagonist tropisetron, are helpful. Recent nutraceutical formulations containing the natural anti-inflammatory and mast cell inhibitory flavonoid quercetin hold promise since they can be used together with other treatment modalities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arnold, L. M., Hudson, J. I., Hess, E. V., Ware, A. E., Fritz, D. A., Auchenbach, M. B., Starck, L. O., & Keck, P. E. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20042 · Cited by 454
Enestrbm, S., Bengtsson, A., & Frddin, T. (1997) · Scandinavian Journal of Rheumatology · doi:10.3109/03009749709105321 · Cited by 62
Cited by
Differential release of mast cell mediators and the pathogenesis of inflammation
Theoharides, T. C., Kempuraj, D., Tagen, M., Conti, P., & Kalogeromitros, D. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00519.x · Cited by 425
Self-citationNeurobiology of depression, fibromyalgia and neuropathic pain
Maletic, V. (2009) · Frontiers in Bioscience · doi:10.2741/3598 · Cited by 366
Potential Mechanisms Underlying Centralized Pain and Emerging Therapeutic Interventions
Eller-Smith, O. C., Nicol, A. L., & Christianson, J. A. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00035 · Cited by 227
“MC are a significant source of both NGF and SP (Leon et al., 1994) and, as discussed in the previous section, are activated and increased in a number of centralized pain disorders (Theoharides et al., 2001, 2005; Lucas et al., 2006; Walker et al., 2011).”
BackgroundMolderings, G. J., Brettner, S., Homann, J., & Afrin, L. B. (2011) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-4-10 · Cited by 149
Are mast cells instrumental for fibrotic diseases?
Overed-Sayer, C., Rapley, L., Mustelin, T., & Clarke, D. L. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00174 · Cited by 105
Metadata
- Authors
- Lucas, H. J., Brauch, C. M., Settas, L., & Theoharides, T. C.
- Venue
- International Journal of Immunopathology and Pharmacology
- Publisher
- SAGE Publications
- Published
- 2006-01
- Volume
- 19
- Issue
- 1
- Pages
- 5-10
- ISSN
- 0394-6320 (ISSN-L)
- 2058-7384
- OpenAlex
- W158945528
- Cited by
- 97
- References
- 2
- FWCI
- 4.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.